Related references
Note: Only part of the references are listed.Interleukin-23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy
Charlie Bridgewood et al.
IMMUNOLOGICAL REVIEWS (2020)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
Philip J. Mease et al.
RMD OPEN (2020)
EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES
D. Mcgonagle et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study
Kenneth B. Gordon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis
Joachim Sieper et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Tildrakizumab: A Review of Phase II and III Clinical Trials
Sree S. Kolli et al.
ANNALS OF PHARMACOTHERAPY (2019)
Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?
Stefan Siebert et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
The microbiome in spondyloarthritis
Maxime Breban et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2019)
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
Desiree van der Heijde et al.
JOURNAL OF RHEUMATOLOGY (2018)
Psoriatic arthritis 1 The pathogenesis of psoriatic arthritis
Douglas J. Veale et al.
LANCET (2018)
Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison
Joy Feld et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Rapid Onset of Inflammatory Bowel Disease alter Receiving Secukinumab Infusion
Jingzhou Wang et al.
ACG CASE REPORTS JOURNAL (2018)
Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Peter Nash et al.
RHEUMATOLOGY AND THERAPY (2018)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich et al.
LANCET (2017)
Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort
William Tillett et al.
RHEUMATOLOGY (2017)
Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis
Smriti K. Raychaudhuri et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
Salvatore D'Angelo et al.
OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS (2017)
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
Yanli Zhuang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype
Muhammad Haroon et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes et al.
LANCET (2015)
Efficacy and Safety of Intravenous Secukinumab in Noninfectious Uveitis Requiring Steroid-Sparing Immunosuppressive Therapy
Erik Letko et al.
OPHTHALMOLOGY (2015)
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double- blind randomised placebo- controlled study (RAPID-PsA)
P. J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires
Muhammad Haroon et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
TH17 Cell Induction and Effects of IL-17A and IL-17F Blockade in Experimental Colitis
Esben Gjerloff Wedebye Schmidt et al.
INFLAMMATORY BOWEL DISEASES (2013)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials
Andrew D. Dick et al.
OPHTHALMOLOGY (2013)
Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis
Lihi Eder et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study
Georg Schett et al.
ARTHRITIS AND RHEUMATISM (2012)
IL-23 Is Critical for Induction of Arthritis, Osteoclast Formation, and Maintenance of Bone Mass
Iannis E. Adamopoulos et al.
JOURNAL OF IMMUNOLOGY (2011)
Obesity in Early Adulthood as a Risk Factor for Psoriatic Arthritis
Razieh Soltani-Arabshahi et al.
ARCHIVES OF DERMATOLOGY (2010)
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2009)
New insights into the pathogenesis and genetics of psoriatic arthritis
Kristine E. Nograles et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2009)
Environmental risk factors for the development of psoriatic arthritis: results from a case-control study
E. Pattison et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis
Pauline Y. P. C. Ho et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2005)
Epidemiology of psoriatic arthritis in the population of the United States
JM Gelfand et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
C Antoni et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Etanercept treatment of psoriatic arthritis - Safety, efficacy, and effect on disease progression
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2004)
Share Paper
